Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-x24gv Total loading time: 0 Render date: 2024-05-16T18:26:43.130Z Has data issue: false hasContentIssue false

Chapter 31 - Lessons and challenges of trials for other nonmotor complications of Parkinson's disease

from Section IV - Clinical Trials in Parkinson's Diease: Lessons, Controversies and Challenges

Published online by Cambridge University Press:  05 March 2016

By
Federico E. Micheli  and
Carlos Zúñiga-Ramírez
Edited by
Néstor Gálvez-Jiménez ,
Hubert H. Fernandez ,
Alberto J. Espay  and
Susan H. Fox
Néstor Gálvez-Jiménez
Affiliation:
Cleveland Clinic, Florida
Hubert H. Fernandez
Affiliation:
Cleveland Clinic, Ohio
Alberto J. Espay
Affiliation:
University of Cincinnati
Susan H. Fox
Affiliation:
Toronto Western Hospital
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Parkinson's Disease
Current and Future Therapeutics and Clinical Trials
 , pp. 337 - 348
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Marks, L, Turner, K, O'Sulliva, J, Deighton, B, Lees, A. Drooling in Parkinson's disease: a novel speech and language therapy intervention. Int J Lang Commun Disord 2001; 36 (Suppl.): 282–7.CrossRefGoogle ScholarPubMed
Mancini, F, Zangaglia, R, Cristina, S, et al. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 2003; 18: 685–8.Google Scholar
Lagalla, G, Millevolte, M, Capecci, M, Provinciali, L, Ceravolo, MG. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2006; 21: 704–7.Google Scholar
Ondo, WG, Hunter, C, Moore, W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 2004; 62: 37–40.CrossRefGoogle ScholarPubMed
Lagalla, G, Millevolte, M, Capecci, M, Provinciali, L, Ceravolo, MG. Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling. J Neurol 2009; 256: 563–7.Google Scholar
Chinnapongse, R, Gullo, K, Nemeth, P, Zhang, Y, Griggs, L. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial. Mov Disord 2012; 27: 219–26.Google Scholar
Thomsen, TR, Galpern, WR, Asante, A, Arenovich, T, Fox, SH. Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease. Mov Disord 2007; 22: 2268–73.Google Scholar
Arbouw, ME, Movig, KL, Koopmann, M, et al. Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial. Neurology 2010; 74: 1203–7.CrossRefGoogle ScholarPubMed
Lloret, SP, Nano, G, Carrosella, A, Gamzu, E, Merello, M. A double-blind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the short-term relief of sialorrhea symptoms in Parkinson's disease patients. J Neurolog Sci 2011; 310: 248–50.Google Scholar
Troche, MS, Okun, MS, Rosenbek, JC, et al. Aspiration and swallowing in Parkinson disease and rehabilitation with EMST A randomized trial. Neurology 2010; 75: 1912–19.Google Scholar
Manor, Y, Mootanah, R, Freud, D, Giladi, N, Cohen, JT. Video-assisted swallowing therapy for patients with Parkinson's disease. Parkinsonism Relat Disord 2013; 19: 207–11.Google Scholar
Baijens, LW, Speyer, R, Passos, VL, et al. The effect of surface electrical stimulation on swallowing in dysphagic Parkinson patients. Dysphagia 2012; 27: 528–37.Google Scholar
Heijnen, BJ, Speyer, R, Baijens, LW, Bogaardt, HC. Neuromuscular electrical stimulation versus traditional therapy in patients with Parkinson's disease and oropharyngeal dysphagia: effects on quality of life. Dysphagia 2012; 27: 336–45.Google Scholar
Sullivan, KL, Staffetti, JF, Hauser, RA, Dunne, PB, Zesiewicz, TA. Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease. Mov Disord 2006; 21: 115–16.CrossRefGoogle ScholarPubMed
Zangaglia, R, Martignoni, E, Glorioso, M, et al. Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study. Mov Disord 2007; 22: 1239–44.Google Scholar
Ondo, WG, Kenney, C, Sullivan, K, et al. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. Neurology 2012; 78: 1650–4.Google Scholar
Locke, MC, Wu, SS, Foote, KD, et al. Weight changes in subthalamic nucleus vs globus pallidus internus deep brain stimulation: results from the COMPARE Parkinson disease deep brain stimulation cohort. Neurosurgery 2011; 68: 1233–7.CrossRefGoogle ScholarPubMed
Kabay, SC, Kabay, S, Yucel, M, Ozden, H. Acute urodynamic effects of percutaneous posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with Parkinson's disease. Neurourol Urodyn 2009; 28: 62–7.Google Scholar
Kulaksizoglu, H, Parman, Y. Use of botulinim toxin-A for the treatment of overactive bladder symptoms in patients with Parkinson's disease. Parkinsonism Relat Disord 2010; 16: 531–4.CrossRefGoogle Scholar
Vaughan, CP, Juncos, JL, Burgio, KL, et al. Behavioral therapy to treat urinary incontinence in Parkinson disease. Neurology 2011; 76: 1631–4.CrossRefGoogle ScholarPubMed
Hussain, IF, Brady, CM, Swinn, MJ, Mathias, CJ, Fowler, CJ. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 2001; 71: 371–4.Google Scholar
Safarinejad, MR, Taghva, A, Shekarchi, B, Safarinejad, S. Safety and efficacy of sildenafil citrate in the treatment of Parkinson-emergent erectile dysfunction: a double-blind, placebo-controlled, randomized study. Int J Impot Res 2010; 22: 325–35. Retraction: Int J Impot Res 2011; 23: 94.Google Scholar
Abate, G, Polimeni, RM, Cuccurullo, F, Puddu, P, Lenzi, S. Effects of indomethacin on postural hypotension in Parkinsonism. Br Med J 1979; 2: 1466.CrossRefGoogle ScholarPubMed
Schoffer, KL, Henderson, RD, O'Maley, K, O'sullivan, JD. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. Mov Disord 2007; 22: 1543–9.Google Scholar
Djaldetti, R, Yust-Katz, S, Kolianov, V, Melamed, E, Dabby, R. The effect of duloxetine on primary pain symptoms in Parkinson disease. Clin Neuropharmacol 2007; 30: 201–5.Google Scholar
Dellapina, E, Ory-Magne, F, Regragui, W, et al. Effect of subthalamic deep brain stimulation on pain in Parkinson's disease. Pain 2012; 153: 2267–73.Google Scholar
Marques, A, Chassin, O, Morand, D, et al. Central pain modulation after subthalamic nucleus stimulation: a crossover randomized trial. Neurology 2013; 81: 633–40.Google Scholar
Högl, B, Saletu, M, Brandauer, E, et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 2002; 25: 905–9.Google Scholar
Adler, CH, Caviness, JN, Hentz, JG, Lind, M, Tiede, J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord 2003; 18: 287–93.Google Scholar
Ondo, WG, Fayle, R, Atassi, F, Jankovic, J. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry 2005; 76: 1636–9.CrossRefGoogle ScholarPubMed
Postuma, RB, Lang, AE, Munhoz, RP, et al. Caffeine for treatment of Parkinson disease A randomized controlled trial. Neurology 2012; 79: 651–8.CrossRefGoogle ScholarPubMed
Medeiros, CA, Carvalhedo de Bruin, PF, Lopes, LA, et al. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. J Neurol 2007; 254: 459–64.Google Scholar
Dowling, GA, Mastick, J, Colling, E, et al. Melatonin for sleep disturbances in Parkinson's disease. Sleep Med 2005; 6: 459–66.Google Scholar
Menza, M, Dobkin, RD, Marin, H, et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Mov Disord 2010; 25: 1708–14.Google Scholar
Larsson, V, Aarsland, D, Ballard, C, Minthon, L, Londos, E. The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. Int J Geriatr Psychiatry 2010; 25: 1030–8.Google Scholar
Di Giacopo, R, Fasano, A, Quaranta, D, et al. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease. Mov Disord 2012; 27: 559–61.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×